Edesa Biotech, Inc. EDSA

EDSA Company Overview

Edesa Biotech, Inc. is a Canadian biopharmaceutical company focused on developing host-directed therapeutics and immune-inflammatory treatments for dermatological and respiratory diseases. The company operates primarily in the biotechnology and specialty pharmaceutical sectors, with research centered on inflammatory pathways and unmet medical needs. Edesa’s pipeline has included investigational treatments for acute respiratory distress syndrome (ARDS), vitiligo, and inflammatory skin disorders. Its business model is driven primarily by clinical-stage drug development, intellectual property generation, and strategic advancement of therapeutic candidates through regulatory pathways.

The company’s principal product candidates have included EB05, an anti-CXCL10 monoclonal antibody evaluated for inflammatory lung conditions, and earlier-stage dermatology assets targeting chronic inflammatory disorders. Edesa was founded in 2015 and became publicly traded on Nasdaq under the ticker EDSA. Since its formation, the company has evolved from a dermatology-focused biotechnology enterprise into a broader immuno-inflammatory development company with an emphasis on therapies addressing severe inflammatory responses and immune dysregulation.